• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

A Look at Web3 and Psychedelic IP

Patrick McConnell by Patrick McConnell
October 13, 2022
in Industry
Reading Time: 5 mins read
A A
A Look at Web3 and Psychedelic IP

Psychedelics have been teaching us about more than just mental health. Questions like what consciousness is and how it can be studied are now on the table. At the same time, larger societal issues like inclusion, indigenous reciprocity, and political bias have been highlighted with a psychedelic lens.

Perhaps the most popular (and controversial) topic highlighted by psychedelics is the patent system. As companies move themselves toward the potential commercialization of psychedelic medicines, a great deal of speculation and attention is being placed on intellectual property (IP).

Psychedelic Intellectual Property and Web3

The problems with the patent system and how it relates to psychedelics have been covered in-depth (also see this in-depth analysis by Shayla Love). Systemic problems in the pharmaceutical industry are common knowledge at this point, with the track record that exists monopolies on medicine have good reason to make people uncomfortable.

There is public outcry concerning monopolies on substances many consider sacred or that others see as a powerful tool to balance a mental health crisis. Yet, this kind of friction can be the incentive for innovators to find workarounds and new systems.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

One such space is Web3 and cryptocurrencies. So a group of biotech-focused startups are looking to bring new sources of funding, niche research topics, and the participation of many more people in the creation and management of intellectual property.

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

The ideas are experimental and still in their early days, with the kinks of tokens, NFTs, and DAOS not fully understood yet. However, instead of griping about a broken system, perhaps an investigation of innovation is warranted.

 

How Web3, NFTs, and DAOs fit into IP

The value of Web3 IP lies not in the price of Bitcoin but in how a distributed ledger or blockchain technology has facilitated the creation of NFTs and DAOs.

NFT stands for “non-fungible token,” a smart contract (a bunch of code) living on a blockchain representing ownership. NFTs use the advanced cryptography of the blockchain to verify ownership, making NFTs immutable and transparent — so they are hard to tamper with, and ownership of an NFT is easy to verify.

What most of us know as NFTs are pictures of monkeys with seemingly bloated valuations. However, NFTs can be much more than digital art. NFTs can be personal documents, datasets, or even intellectual property. NFTs that are IP are known as IP-NFTs. What makes IP-NFTs unique is the ease at which they can be fractionalized, meaning ownership is shared among many parties.

Fractionalized ownership has become popular with DAOs, or decentralized autonomous organizations. DAOs are smart contracts that perform organizations’ functions using distributed ledger technology. DAOs often make decisions for organizations by facilitating voting among stakeholders in a project. It’s a new concept, but believers envision DAOs to be the LLCs of the blockchain.

With IP-NFT, a project can create and distribute a piece of IP amongst stakeholders, who can then vote on the IPs management through the DAO.

Chris Byrnes, an IP Strategist and Patent Attorney sums it up with:

[bsa_pro_ad_space id=2]
ADVERTISEMENT

“IP-NFTs network IP into a co-governed knowledge commons, run as a DAO. The IP can be enforced against infringers either independently or as part of a co-governed collective.”

 

 

Why Fractionalize Ownership?

Collective ownership is attractive because it democratizes participation in research and ownership. Traditionally, creating and owning IP is very exclusive. IP created will be used to serve the interests of its creators.

While this is all business as usual, it leaves some groups out in the cold. Chris Byrnes explains that fractionalized ownership using a DAO ensures “members can maintain autonomy to enforce their own IP against infringers while also co-governing the commercialization of the DAO’s collective IP network.”

An example is AthenaDAO

Fresh Lasix For Sale

 which saw an underrepresentation of women’s reproductive health in research. The group created a DAO that now can utilize Web3 to crowd-fund research that would otherwise require monumental effort within established institutions. There is also a startup focused on democratizing psychedelic research, PsyDAO which is focused on creating IP for the public good.

 

Other Benefits to IP-NFT

Byrnes elaborates that ownership of IP-NFT can be easily tracked and verified by the blockchain, making coordination of licensing or royalties fast, easy, and cheap. With the blockchain quickly verifying IP ownership or history, disputes can be settled without exorbitant fees of legal battles.

In industries like psychedelics that rely on IP plays, there can be what is called the “Valley of Death.”

Patent Attorney Savva Kerdemelidis alludes to the gap between early-stage research in the lab actually being applied. For example, a huge percentage of discoveries made in universities don’t ever turn into something that helps people. Even if a drug is created, it will be dropped if a monopoly price cannot be enforced or as soon as its patent expires — another situation Kerdemelidis is trying to remedy with pay-for-success contracts.

Kerdemelidis explains that an IP-NFT is potentially more flexible in crossing The Valley of Death because it can be traded on IP markets in real-time, like via Molecule’s platform, and ownership can be distributed throughout stakeholder groups like patients while being linked to clinical trial data or protocols before being spun off into a company.

 

 

Challenges of IP-NFT

While some of the flexibility and social aspects of projects using IP-NFT are attractive, DAOs and NFTs are not everyone’s comfort zone.

DAOs have different governance models that can be exploited in unique ways, notably by a person or organization buying up tokens used for governance. Considering patent trolls, it’s not out of the question. Debates around the best voting system for DAOs are also not settled, and accountability can be challenging with decentralized voting. However, Kerdemelidis assured us that better tooling, templates, and conventions could solve this.

The legal architecture, too, is a mixture of established models and new experiments.

Chris Byrnes says the legal architecture of IP-NFT is “a private contract layer on top of court-tested and decades-old Open Source and Creative Commons licenses.” He adds that wrapping IP-NFTs with IP licenses is more experimental but that there is no known legal or regulatory precedent, making IP-NFT commons risker activity than traditional IP commons. To date, there are no rulings on IP-NFT networks and open-access licenses. So while admittedly experimental, there are some established frameworks that DAOs and IP-NFT can work within.

DAOs are new, we’re exploring an unknown frontier. Yet, considering the diversity of people involved or wanting to be involved in psychedelics, from ancient shamanistic lineages and hippies from the 60s, to venture capitalists and therapists of the 2020s — fractionalized ownership might have a place in the future of psychedelics and its surrounding industries.

 

Interested in more like this? Check out Decentralizing the Future: Crypto and Psychedelics

Tags: Intellectual propertypatentsWeb3
Patrick McConnell

Patrick McConnell

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Next Post
Mydecine Releases 2021 Financials and Announces Capital Raise

Palo Santo Closes $50 Million Psychedelic Investment Fund

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.